|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM377952095 |
| 003 |
DE-627 |
| 005 |
20241107232335.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240923s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202412340
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1593.xml
|
| 035 |
|
|
|a (DE-627)NLM377952095
|
| 035 |
|
|
|a (NLM)39308257
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Fan, Miao
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Reversing Immune Checkpoint Inhibitor-Associated Cardiotoxicity via Bioorthogonal Metabolic Engineering-Driven Extracellular Vesicle Redirecting
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 07.11.2024
|
| 500 |
|
|
|a Date Revised 07.11.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a The cardiotoxicity induced by immune checkpoint inhibitors (ICIs) is associated with high mortality rates. T cells play an important role in ICI-induced cardiac injury. The inhibition of local T-cell activity is considered an effective strategy for alleviating ICI-related cardiotoxicity. Tumor-derived extracellular vesicles (EVs) contribute to immunosuppression via PD-L1 overexpression. In this study, a bioorthogonal metabolic engineering-driven EV redirecting (Biomeder) strategy for in situ engineered EVs with myocardial-targeting peptides is developed. Accumulated tumor-derived EV (TuEVs) reverses the immune environment in the heart by increasing PD-L1 levels in cardiomyocytes and/or by directly inhibiting T-cell activity. More importantly, it is found that the redirection of TuEVs further disrupts immunosuppression in tumors, which facilitates anti-tumor activity. Thus, redirecting TuEVs to the heart simultaneously enhances the antitumor efficacy and safety of ICI-based therapy. Furthermore, the Biomeder strategy is successfully expanded to prevent ICI-induced type 1 diabetes. This Biomeder technique is a universal method for the treatment of various ICI-related adverse events
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a ICI‐induced T1D
|
| 650 |
|
4 |
|a ICI‐induced cardiotoxicity
|
| 650 |
|
4 |
|a bioorthogonal metabolic engineering
|
| 650 |
|
4 |
|a cardio‐oncology
|
| 650 |
|
4 |
|a extracellular vesicles
|
| 650 |
|
7 |
|a Immune Checkpoint Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a B7-H1 Antigen
|2 NLM
|
| 700 |
1 |
|
|a Zhang, Xing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Huifang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Lanya
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Fei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Luo, Li
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, Xiaohan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liang, Xing-Jie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Jinchao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Zhenhua
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 45 vom: 31. Nov., Seite e2412340
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:45
|g day:31
|g month:11
|g pages:e2412340
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202412340
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 45
|b 31
|c 11
|h e2412340
|